Schneider M P, Erdmann J, Delles C, Fleck E, Regitz-Zagrosek V, Schmieder R E
Department of Medicine/Nephrology, University of Erlangen-Nürnberg, Germany.
J Hypertens. 2000 Dec;18(12):1767-73. doi: 10.1097/00004872-200018120-00010.
To test whether the Glu298Asp polymorphism of the endothelial nitric oxide synthase (eNOS) gene is of functional relevance in humans by altering endothelium-dependent vasodilation.
The Asp298 variant of the eNOS gene product has been associated with arterial hypertension, coronary artery disease and myocardial infarction. The pathogenetic mechanism has not yet been elucidated. Since endothelium-dependent vasodilation has been shown to be impaired in these disorders, we hypothesized that the Glu298Asp polymorphism of the eNOS gene influences endothelium-dependent vasodilation.
In 80 patients with normal or elevated cholesterol, endothelium-dependent and -independent vasodilation was assessed. Forearm blood flow was measured by plethysmography in response to intra-arterial (i.a.) infusion of 12 and 48 microg/min acetylcholine and 3.2 and 12.8 microg/min nitroprusside, respectively. NG-monomethyl-L-arginine (L-NMMA) in doses of 4, 8 and 16 micromol/min was infused to test basal nitric oxide (NO) production and release. Genomic DNA was extracted from blood samples to determine the Glu298Asp polymorphism of the eNOS gene at position 1917 G/T after BanII restriction.
Baseline parameters (age, gender, blood pressure, body mass index, cholesterol level) were similar across the genotypes. Genotype frequencies did not deviate from the Hardy-Weinberg equilibrium. No differences in forearm blood flow to i.a. acetylcholine (average increase: + 554 +/- 371%), nitroprusside or L-NMMA infusion were found across the eNOS genotypes, neither for endothelium-dependent or endothelium-independent vasodilation, nor for basal NO production and release. Our sample size of n = 80 had a power of > 80% (beta = 0.20) with a P value < 0.05 (alpha = 0.05) to detect a 200% difference in forearm blood flow response to 48 microg/min acetylcholine.
At a power of 80%, we can exclude a relevant effect on endothelium-dependent vasodilation due to the eNOS Glu298Asp polymorphism. Thus, our functional genetic study does not suggest any biological effect of the eNOS Glu298Asp genotype on the cardiovascular system via an influence on endothelium-dependent vasodilation.
通过改变内皮依赖性血管舒张功能,来检测内皮型一氧化氮合酶(eNOS)基因的Glu298Asp多态性在人类中是否具有功能相关性。
eNOS基因产物的Asp298变体与动脉高血压、冠状动脉疾病和心肌梗死有关。其发病机制尚未阐明。由于在这些疾病中已显示内皮依赖性血管舒张功能受损,我们推测eNOS基因的Glu298Asp多态性会影响内皮依赖性血管舒张。
对80例胆固醇正常或升高的患者进行内皮依赖性和非内皮依赖性血管舒张功能评估。通过体积描记法测量前臂血流量,分别响应动脉内(i.a.)输注12和48微克/分钟的乙酰胆碱以及3.2和12.8微克/分钟的硝普钠。以4、8和16微摩尔/分钟的剂量输注NG-单甲基-L-精氨酸(L-NMMA),以检测基础一氧化氮(NO)的产生和释放。从血样中提取基因组DNA,在BanII酶切后测定eNOS基因第1917位G/T处的Glu298Asp多态性。
各基因型的基线参数(年龄、性别、血压、体重指数、胆固醇水平)相似。基因型频率未偏离哈迪-温伯格平衡。在eNOS各基因型中,无论是内皮依赖性还是非内皮依赖性血管舒张,以及基础NO的产生和释放,前臂血流量对动脉内乙酰胆碱(平均增加:+554±371%)、硝普钠或L-NMMA输注均无差异。我们n = 80的样本量在P值<0.05(α = 0.05)时,检测前臂血流量对48微克/分钟乙酰胆碱反应差异达200%的效能>80%(β = 0.20)。
在效能为80%时,我们可以排除eNOS基因Glu298Asp多态性对内皮依赖性血管舒张的相关影响。因此,我们的功能遗传学研究未提示eNOS基因Glu298Asp基因型通过影响内皮依赖性血管舒张对心血管系统产生任何生物学效应。